Oruka Therapeutics is focused on improving the experiences of people living with plaque psoriasis, psoriatic arthritis, and other dermatologic and inflammatory indications. Self-described as committed to advancing potentially best-in-class monoclonal antibodies for treatment.

Oruka Therapeutics

Celgene Corporation is a biopharmaceutical company specializing in the development and commercialization of cancer and immunology drugs. Its major product is Revlimid (lenalidomide), used in the treatment of multiple myeloma and certain anemias.

Sol Barer

Robert J. Hariri

Celgene Corporation

Oruka Therapeutics | 2,597 followers on LinkedIn. A new era for chronic skin diseases | Advancing novel biologics that aim to offer the greatest possible freedom from disease to people with plaque psoriasis and other associated conditions

Biopharmaceutical Quality Operations Management

Katherine Guise, CQA

VP, Medical Affairs at Oruka Therapeutics

Eugenia Levi

Sr. Director, Clinical Data Management

Evelyn Dorsey

Vice President Regulatory Affairs at Oruka Therapeutics

Jodi Parsons

October 29 is #WorldPsoriasisDay . This year’s theme of “Family” highlights the impact of psoriatic disease on over 100 million people worldwide as well as their loved ones. Psoriasis presents unique challenges not only for those affected but also for their families. At Oruka, we’re dedicated to developing new treatments that aim to ease this burden by offering those living with psoriasis the greatest possible freedom from disease.

We recently celebrated our public listing at the Nasdaq MarketSite in Times Square! We’re proud to mark this achievement along our path to develop novel biologics for plaque psoriasis and related conditions. Photography courtesy of Nasdaq, Inc.

We’re excited to present new preclinical data on ORKA-001, a novel extended half-life monoclonal antibody targeting IL-23p19, at the EADV Congress in Amsterdam. The data show that ORKA-001 has a three-fold longer half-life in non-human primates than risankizumab, while binding to a similar epitope with similar affinity. These findings give us additional confidence that ORKA-001 can achieve our base-case expectation of dosing once every six months and further reason to believe we could reach once-yearly dosing with the potential for higher efficacy, all with the goal of offering people with psoriasis the most possible freedom from their disease.

We’re excited to begin trading on Nasdaq as “ORKA” today following the close of our merger. This transaction and concurrent $275 million financing propel us towards our goal of offering the greatest possible freedom from disease to patients with psoriasis and other associated diseases.

Metric
Company Name	Oruka Therapeutics	Celgene Corporation
Symbol
MSH ID	COM:ORUKATX	COM:CELGENE
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	US
Stage	Post-IPO Equity
Employee Count		10.00K
Website	orukatx.com	celgene.com
LinkedIn	oruka-therapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	1.26K
Web Traffic Growth	0.67
Valuation
Raised Capital	275M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ORUK

COM:ORUKATX

Oruka Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue